The PDL1 expression in subtype 2 was significantly lower than the other three subtypes (ANOVA, p = 0.000891), suggesting patients with subtypes 1, 3 and 4 of meningioma likely benefit from immune checkpoint blockade (Figure 4C). The gene discussed is CD274; the disease is meningioma.